Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 11/20 | 0.55 |
| ▸ | CHRNA3 | P32297 | 11/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8151174 | 0.94 | CHRNB4 (0.64) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL4693339 | 0.78 | CHRNB4 (0.55) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL3574404 | 0.78 | CHRNB4 (0.55) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL15665457 | 0.78 | CHRNB4 (0.55) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL2045328 | 0.78 | CHRNB4 (0.57) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL23892004 | 0.78 | CHRNB4 (0.50) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL165812 | 0.77 | CHRNB4 (0.87) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL433117 | 0.76 | CHRNB4 (0.90) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL19072298 | 0.74 | NPC1 (0.42) | ALDH1A1MAPK14NPC1PKMRAB9A | |
| SCHEMBL28386854 | 0.74 | CHRNB4 (0.50) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144850-A1 | INDOLO HEPTAMYL OXIME ANALOGUE AS PARP INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-05-12 | — | — | US | disclosed |
| CN-109988091-B | Preparation method of imine compound | 苏州大学 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144850-A1 | INDOLO HEPTAMYL OXIME ANALOGUE AS PARP INHIBITOR | PARP1, PARP2, PARP3 | CHRNB4 2354/4885CHRNA3 1574/4885ALDH1A1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.